文献速递前列腺癌

恩扎卢胺对比比卡鲁胺在年轻与老年转移性去势抵抗性前列腺癌患者中的疗效与安全性:TERRAIN试验事后分析

Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial.
PubMed 文献 · J Urol · 2017-08-19

TERRAIN试验事后分析按年龄(<75岁 vs ≥75岁)评估恩扎卢胺对比比卡鲁胺的疗效与安全性。恩扎卢胺在<75岁组(HR 0.38,95%CI 0.27-0.52,p<0.0001)和≥75岁组(HR 0.59,95%CI 0.37-0.92,p=0.018)均显著降低疾病进展或死亡风险;至PSA进展时间在两组中也均显著延长。≥75岁者跌倒与心脏事件增多,作者建议对有显著合并症的老年患者处方时需谨慎。

要点

  • 恩扎卢胺较比卡鲁胺显著降低<75岁患者疾病进展或死亡风险(HR 0.38)。
  • 恩扎卢胺较比卡鲁胺显著降低≥75岁患者疾病进展或死亡风险(HR 0.59)。
  • ≥75岁患者跌倒与心脏事件增多,处方有显著合并症者需谨慎。

核心结论

  • 恩扎卢胺较比卡鲁胺改善临床结局,且不受年龄影响;但≥75岁患者跌倒与心脏事件增加,提示对有显著合并症的老年患者处方时需谨慎。

研究设计与样本

  • TERRAIN试验的事后分析,患者按1:1随机接受恩扎卢胺160 mg/日或比卡鲁胺50 mg/日。
  • 按年龄<75岁与≥75岁分亚组,事后分析无进展生存、至前列腺特异性抗原进展时间与安全性。

主要发现

  • 恩扎卢胺较比卡鲁胺显著降低<75岁患者疾病进展或死亡风险(HR 0.38,95%CI 0.27-0.52,p<0.0001)。
  • 恩扎卢胺较比卡鲁胺显著降低≥75岁患者疾病进展或死亡风险(HR 0.59,95%CI 0.37-0.92,p=0.018)。
  • 至前列腺特异性抗原进展时间在<75岁与≥75岁亚组中恩扎卢胺均较比卡鲁胺显著延长。
  • ≥75岁接受恩扎卢胺者心房颤动、尿路感染、跌倒及食欲下降较多(亚组间差异≥5%),而肢体疼痛与潮热较少。
  • ≥75岁接受比卡鲁胺者背痛与潮热较少;≥75岁患者3级及以上心脏事件较<75岁者更频繁。

临床怎么用

  • 作者认为,恩扎卢胺较比卡鲁胺改善临床结局且不受年龄影响。
  • 作者指出,≥75岁患者跌倒与心脏事件增加,对有显著合并症的老年患者处方时需谨慎。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Enzalutamide significantly prolonged median progression-free survival vs bicalutamide in chemotherapy naïve men with metastatic castration resistant prostate cancer in the TERRAIN (Enzalutamide versus Bicalutamide in Castrate Men with Metastatic Prostate Cancer) trial. In this post hoc analysis we investigated the influence of age on the efficacy and safety of enzalutamide vs bicalutamide in this population. MATERIALS AND METHODS: Patients were randomized 1:1 to enzalutamide 160 mg per day or bicalutamide 50 mg per day. Progression-free survival, time to prostate specific antigen progression and safety were analyzed post hoc in younger (age less than 75 years) and older (age 75 years or greater) subgroups. RESULTS: Enzalutamide significantly reduced the risk of disease progression or death vs bicalutamide in patients younger than 75 years (HR 0.38, 95% CI 0.27-0.52, p <0.0001) and 75 years old or older (HR 0.59, 95% CI 0.37-0.92, p = 0.018). Time to prostate specific antigen progression was also significantly prolonged with enzalutamide vs bicalutamide in each subgroup. The adverse event distribution between treatments was similar in each subgroup except for more (5% or greater difference between subgroups) atrial fibrillation, urinary tract infections, falls and decreased appetite as well as less extremity pain and hot flushing in enzalutamide treated patients 75 years old or older, and less back pain and hot flushing in bicalutamide treated patients 75 years old or older. Grade 3 or greater cardiac events were more frequent in enzalutamide treated and bicalutamide treated patients who were 75 years old or older vs younger than 75 years. Fatigue was more frequent in enzalutamide treated patients with a similar distribution in each age subgroup. CONCLUSIONS: Enzalutamide improved clinical outcomes vs bicalutamide irrespective of age. Increased falls and cardiac events suggest caution when prescribing to older patients (age 75 years or greater) with significant comorbidity.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Siemens DR, Klotz L, Heidenreich A, et al. Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial. J Urol. 2017. PMID: 28827103. doi:10.1016/j.juro.2017.08.080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。